Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

ash and equivalents, and we have no long-term debt. We believe our financial resources position us well for the future, and provide us with increased ability to consider promising opportunities that fit the criteria of our growth strategy."

Recent Highlights

  • In November 2012, the Company completed the public offering of 3,680,000 shares of class A common stock, which included 840,000 shares from selling stockholder El.En. S.p.A. The offering resulted in net proceeds of approximately $55.3 million to the Company.
  • The Company announced on December 4, 2012 that it received 510(k) clearance from the U.S. Food and Drug Administration to market the PicoSure™ laser workstation for the removal of tattoos and benign pigmented lesions. The Company expects to sell PicoSure initially through its U.S. direct sales force to aesthetic dermatologists and plastic surgeons. The Company plans to launch PicoSure in March 2013 at the Annual Meeting of the American Academy of Dermatology.
  • Business Outlook 
    "We capped a successful 2012 with our fifth consecutive quarter of profitability and record revenue on both a quarterly and full-year basis," Davin said. "We believe we enter 2013 poised for another year of profitable growth. We are excited for the launch of our newest flagship device, PicoSure, for the removal of tattoos and benign pigmented lesions.  After nearly a decade of research and development, this device provides us with a first-mover advantage in a large and underserved market. In addition, we expect that Cynosure's first home-use device, developed in partnership with Unilever, for the treatment of facial wrinkles will be commercially launched by Unilever in 2013." 

    Fourth-Quarter Financial Results Conference CallIn conjunction with the announcement of its fourth-quarter and year-end 2012 financial results, Cynosure will host a conference call for investors and an
    '/>"/>

    SOURCE Cynosure, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
    2. Cynosure Announces Upcoming Conference Presentations
    3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
    4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
    5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
    6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
    7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
    8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... DIEGO, July 29, 2015 Neurocrine Biosciences, Inc. (NASDAQ: ... June 30, 2015. For the second quarter of 2015, the Company ... share, compared to a net loss of $13.4 million, or $0.18 ... six months ended June 30, 2015, the Company reported a net ... to net loss of $25.2 million, or $0.35 loss per share, ...
    (Date:7/29/2015)... , July 29, 2015 Immune Pharmaceuticals Inc. ... secured financings of up to $21.5 million through two ... Inc. (NYSE: HTGC ) ("Hercules"), for a term loan ... mutual fund Discover Growth Fund ("Discover"), for the sale ... Preferred Stock ("Preferred Stock") for up to $12 million ...
    (Date:7/29/2015)... DALLAS , July 29, 2015 ... Apnea Devices Market by Product, Diagnostic (PSG, Pulse Oximeter), ... Appliances (Mandibular Advancement Device)], End User (Home Care Settings, ... by MarketsandMarkets, this report studies the global Sleep Apnea ... 2020. This market is expected to reach $5.3 Billion ...
    Breaking Medicine Technology:Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 2Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 3Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 4Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 5Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 6Immune Pharmaceuticals secures funding of up to $21.5 Million from institutional Investors 7Sleep Apnea Devices Market Worth $5.3 Billion by 2020 2Sleep Apnea Devices Market Worth $5.3 Billion by 2020 3Sleep Apnea Devices Market Worth $5.3 Billion by 2020 4
    ... Phase I data from XL880, Phase II data from ... SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --,Exelixis, Inc. ... investigational compounds XL880 and XL999 will be,presented at the ... is being held June 1 to 5 in Chicago,Illinois. ...
    ... many as,first-line in secondary stroke prevention , ... presented today at the,16th European Stroke Conference in ... dipyridamole plus ASA,is marketed as Aggrenox® or Asasantin® ... vascular events in patients who had,a TIA or ...
    Cached Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 2New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 3New Research Confirms the Benefit of Extended-Release Dipyridamole,Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk,Patients 4
    (Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... At the presentation of the 2015 ... discussion was focused on research presented by the Journal of Arthroplasty pertaining to ... – like driving. , Results of the study confirm what Santa Rosa Orthopaedics ...
    (Date:7/30/2015)... ... 30, 2015 , ... World Breast-Feeding Week (Aug. 1-7) was ... have the nutrition required to grow into healthy adults. Medicationdiscountcard.com supports ... prescription pre-natal vitamins. , Folic Acid , Arguably one of the most important ...
    (Date:7/29/2015)... Plano, TX (PRWEB) , ... July 30, 2015 ... ... best content available for their clients, BOC approved provider of online continuing ... six new course offerings to their exclusive Andrews Research and Education Sports Medicine ...
    (Date:7/29/2015)... ... July 29, 2015 , ... Avatar Solutions has received official approval from ... Survey. , The CAHPS for PQRS Survey collects information about patients’ experiences ... eligible providers must participate or they will receive a 2% penalty in 2017. At ...
    (Date:7/29/2015)... ... July 29, 2015 , ... This past week, ... surrogacy journey from a treasured member of the CARE extended family. , By ... to help intended parents across the globe gain a newfound perspective on surrogacy in ...
    Breaking Medicine News(10 mins):Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3
    ... Black Americans with lupus have a higher antibody response to ... This may be good news for black Americans with ... the flu vaccine were more likely to experience moderate to ... a greater response. As many as 322,000 adults in ...
    ... prevents and cures kidney failure in mice sheds light ... potential treatment in people with such illnesses. ... in animals," said study leader Marni J. Falk, M.D., ... at The Children,s Hospital of Philadelphia. "So these striking ...
    ... sperm quality and who are trying to have children should ... cell phone use appears to increase the level of testosterone ... sperm quality and a decrease in fertility. "Our ... postdoctoral fellow in the Department of Pharmacology and Toxicology and ...
    ... 19, 2011) The John Theurer Cancer Center at Hackensack ... Promise Foundation to host a skin cancer screening event on ... feature educational information on skin cancer prevention and offer free ... "Skin cancer can be a devastating disease, but ...
    ... Autnoma de Barcelona researchers have discovered that Viagra drastically ... disease. The research, published in Acta Neuropathologica , ... of the animals after eight days of treatment. Researchers ... out in patients given that the drug is well ...
    ... Today 16 countries announced new commitments to dramatically reduce ... Global Strategy for Women,s and Children,s Health. ... children,s health is reaching new and encouraging heights. The ... prove that saving the lives of the most vulnerable ...
    Cached Medicine News:Health News:Black Americans With Lupus Have Better Response to Flu Vaccine 2Health News:Animal results may pave way to treating rare mitochondrial diseases in children 2Health News:Viagra could reduce multiple sclerosis symptoms 2Health News:New commitments to save women and children 2Health News:New commitments to save women and children 3Health News:New commitments to save women and children 4Health News:New commitments to save women and children 5Health News:New commitments to save women and children 6Health News:New commitments to save women and children 7Health News:New commitments to save women and children 8
    ... of a 384 Well Plate at Once , ... plates, you need a pipettor that can adapt ... you get with our 16-channel Impact pipettor., Available ... innovation was specifically designed to allow you to ...
    ... and Alliance Catheter Delivery System ... introduction of catheters or devices ... a superior approach. These introducers ... peel-away introducer performance with a ...
    The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
    ... System combines low-profile, high radial force, and excellent ... compatible stent system provides 6F sheath / 8F ... 10.0 mm). Now, with longer stents available, the ... lengths (28, 38, 56, 80 and 100 mm) ...
    Medicine Products: